Gefitinib in Combination With Oral Topotecan and Cyclophosphamide in Relapsed Neuroblastoma: Pharmacological Rationale and Clinical Response

作者：Donfrancesco Alberto^*; De Ioris Maria Antonietta; McDowell Heather Prudence; De Pasquale Maria Debora; Ilari Ilaria; Jenkner Alessandro; Castellano Aurora; Cialfi Samantha; De Laurentis Clementina; Dominici Carlo

来源：Pediatric Blood and Cancer, 2010, 54(1): 55-61.

DOI：10.1002/pbc.22219

• EGFR
• neuroblastoma
• oral chemotherapy
• targeted therapy

Aim. Activity and toxiciy of gefitinib in combination with topotecan and cyclophosphamide (CPA) were evaluated in a case-series of relapsed neuroblastoma (NB) patients. The in vitro activity of the combination was also assessed. Procedure. Gefitinib (250 mg/day), topotecan (0.8 mg/m(2)/day), and CPA (50 mg/m(2)/day) (GTC) were administered orally for 14 consecutive days out of 28 clays. Antitumor activity of gefitinib as single agent and in combination with either topotecan or CPA was assessed in a panel of NB cell lines. Results. Ninety-two courses were given in 10 patients. Grade 4 neutropenia was observed in 7/92 courses (8%) and grade 4 thrombocytopenia in 8/92 (9%). Two patients had a grade 2 liver toxicity, four a grade 1/2 skin toxicity, and two a grade 1/2 diarrhea. Dose reduction of topotecan and/or CPA was required in eight patients. After four courses, three patients were in partial response (PR) and four with a stable disease (SD), while three experienced a progressive disease (PD). Time to progression (TTP) was 9 months (range, 1-27). After a median follow-up of 16 months (range 5-54), seven patients are died of disease (DOD) and three alive with disease (AWD). All but one patient discontinued oral chemotherapy because of a PD, whilst one patient stopped chemotherapy after 27 months with a SD. In vitro, gefitinib was synergistic with topotecan and additive with CPA. Conclusion. The GTC combination was well tolerated and the TTP was encouraging. These promising results, also supported by in vitro evidence, should be further confirmed in a phase II Study. Pediatr Blood Cancer 2010;54:55-61.

• 出版日期2010-1